Onconic Therapeutics Inc.
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
476060 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 테헤란로26길 12 제일비젼타워 11층, 강남구
- Website:
- http://onconic.co.kr/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Onconic Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative drugs for cancer and gastrointestinal diseases. A subsidiary of Jeil Pharmaceutical, the company focuses on therapeutic areas with high unmet medical needs and significant market potential. Its development pipeline features novel treatments for acid-related conditions, including ZacuCorrection (zastaprazan), a next-generation potassium-competitive acid blocker (P-CAB) designed to treat gastroesophageal reflux disease. Onconic Therapeutics aims to advance its portfolio through clinical development and strategic collaborations to bring new therapeutic options to patients.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Onconic Therapeutics Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Onconic Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Onconic Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
